CPT Stock Overview
A regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. More details
| Snowflake Score | |
|---|---|
| Valuation | 3/6 |
| Future Growth | 2/6 |
| Past Performance | 0/6 |
| Financial Health | 5/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
My Notes
Capture your thoughts, links and company narrative
CollPlant Biotechnologies Ltd. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$3.76 |
| 52 Week High | US$6.00 |
| 52 Week Low | US$3.00 |
| Beta | 0.56 |
| 1 Month Change | 16.77% |
| 3 Month Change | 2.17% |
| 1 Year Change | -29.06% |
| 3 Year Change | n/a |
| 5 Year Change | -61.44% |
| Change since IPO | -7.78% |
Recent News & Updates
Recent updates
Shareholder Returns
| CPT | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 16.8% | 6.5% | 1.3% |
| 1Y | -29.1% | -1.9% | 9.0% |
Return vs Industry: CPT underperformed the German Biotechs industry which returned -3.7% over the past year.
Return vs Market: CPT underperformed the German Market which returned 10.1% over the past year.
Price Volatility
| CPT volatility | |
|---|---|
| CPT Average Weekly Movement | 12.9% |
| Biotechs Industry Average Movement | 7.3% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.6% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: CPT's share price has been volatile over the past 3 months compared to the German market.
Volatility Over Time: CPT's weekly volatility (13%) has been stable over the past year, but is still higher than 75% of German stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1981 | 75 | Yehiel Tal | www.collplant.com |
CollPlant Biotechnologies Ltd., a regenerative and aesthetic medicine company, focuses on three-dimensional (3D) bioprinting of tissues and organs, and medical aesthetics in the United States, Canada, Israel, Europe, and internationally. Its products are based on recombinant type I human collagen that is produced with its proprietary plant based genetic engineering technology. The company’s products include BioInks for 3D printing of tissues and organs; dermal filler and soft tissue fillers for treating wrinkles; 3D Bioprinted breast implants for regeneration of breast tissue; VergenixSTR, a soft tissue repair matrix intended for the treatment of tendinopathy; and VergenixFG, an advanced wound care product for the treatment of deep surgical incisions and wounds, including diabetic ulcers, venous and pressure ulcers, burns, bedsores, and other chronic wounds; as well as develops injectable breast implants and 3D bioprinted regenerative soft tissue matrix for use in breast reconstruction procedures.
CollPlant Biotechnologies Ltd. Fundamentals Summary
| CPT fundamental statistics | |
|---|---|
| Market cap | €48.83m |
| Earnings (TTM) | -€17.00m |
| Revenue (TTM) | €634.47k |
74.0x
P/S Ratio-2.8x
P/E RatioIs CPT overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CPT income statement (TTM) | |
|---|---|
| Revenue | US$650.00k |
| Cost of Revenue | US$2.13m |
| Gross Profit | -US$1.48m |
| Other Expenses | US$15.94m |
| Earnings | -US$17.42m |
Last Reported Earnings
Sep 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.52 |
| Gross Margin | -227.08% |
| Net Profit Margin | -2,680.00% |
| Debt/Equity Ratio | 0% |
How did CPT perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2025/01/10 12:15 |
| End of Day Share Price | 2025/01/10 00:00 |
| Earnings | 2024/09/30 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
CollPlant Biotechnologies Ltd. is covered by 3 analysts. 2 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Jason Kolbert | D. Boral Capital LLC. |
| Linda Pomeroy | Edison Investment Research |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |